WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018106980) LIPOSOMAL ELINAFIDE FORMULATIONS AND USES THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/106980 International Application No.: PCT/US2017/065229
Publication Date: 14.06.2018 International Filing Date: 08.12.2017
IPC:
A61K 9/00 (2006.01) ,A61K 9/127 (2006.01) ,A61K 31/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
10
Dispersions; Emulsions
127
Liposomes
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
Applicants: MALLINCKRODT LLC[US/US]; 675 McDonnell Boulevard Hazelwood, MO 63042, US
Inventors: McGHEE, William; US
FITCH, Rick; US
Agent: NACKOVIC, Vera; US
Priority Data:
62/431,52408.12.2016US
Title (EN) LIPOSOMAL ELINAFIDE FORMULATIONS AND USES THEREOF
(FR) FORMULATIONS LIPOSOMALES D'ÉLINAFIDE ET UTILISATIONS DE CES DERNIÈRES
Abstract:
(EN) The present invention provides compositions for the treatment of cancer. The compositions include liposomes containing a phosphatidylcholine lipid, a sterol, a PEG-lipid, and elinafide, wherein less than 20% of the elinafide is released in vitro from the liposome within 40 hours. The present invention also provides liposomal compositions for the treatment of cancer comprising administering to a patient in need thereof a liposome, wherein the liposome comprises: a phosphatidylcholine lipid; a sterol; a PEG-lipid; and elinafide, wherein the administration of the liposomal composition has a reduced occurrence of side effects, such as for example, muscle myopathy in the patient.
(FR) La présente invention concerne des compositions pour le traitement du cancer. Les compositions comprennent des liposomes contenant un lipide de type phosphatidylcholine, un stérol, un lipide pégylé et de l'élinafide, moins de 20 % de l'élinafide étant libéré in vitro à partir du liposome en l'espace de 40 heures. La présente invention concerne également des compositions liposomales pour le traitement du cancer, comprenant l'administration au patient le nécessitant d'un liposome, le liposome comprenant : un lipide de type phosphatidylcholine ; un stérol ; un lipide pégylé ; et de l'élinafide, l'administration de la composition liposomale conduisant à une moindre occurrence chez le patient d'effets indésirables, tels que par exemple une myopathie musculaire.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)